Associated tags: Paratriathlon, Glaucoma, Cannabinoid, Safety, Pharmaceutical industry, OTCQB, Trial of the century, OE, CB1, Ocular hypertension, Patient, IOP, Obesity, Eye, Biomarker, Isle of Skye, MD, SAN, THC, Hyperaemia, Cholesterol, OHT
Locations: US, CA, SAN DIEGO
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye’s executive team will present the company and its programs in obesity and glaucoma at the following investment conferences:
Key Points:
- SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye’s executive team will present the company and its programs in obesity and glaucoma at the following investment conferences:
Retrieved on:
Wednesday, April 10, 2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global Market® stock exchange ("Nasdaq").
Key Points:
- SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global Market® stock exchange ("Nasdaq").
- The Company's common stock is expected to commence trading on Nasdaq at the market open on Thursday, April 11th, 2024, under the ticker symbol "SKYE".
- The Company's common stock will no longer trade on the over-the-counter securities market.
- "This listing to the Nasdaq Global Market is a validation of Skye and its recent performance," said Punit Dhillon, Chief Executive Officer and Chairman.
Genomics England,
OTCQB,
SAN,
Senior,
Biotechnology,
Obesity,
Bristol Myers Squibb,
Bayer,
Lieutenant (navy),
Therapy,
Haemophilia,
Organization,
FRCP,
Medicine,
Milken Institute,
Bangladesh Technical Education Board,
MBBS,
Development,
Royal Navy,
Partnership,
Pharmaceutical industry Dr. Jenkins’ esteemed career spans more than 25 years in the global pharmaceutical, biotechnology and life science industry.
Key Points:
- Dr. Jenkins’ esteemed career spans more than 25 years in the global pharmaceutical, biotechnology and life science industry.
- Dr. Jenkins currently provides board level and consulting services to organizations across the life science and healthcare industry.
- As a pharmaceutical thought leader, Dr. Jenkins routinely contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.
- “We are delighted to have someone of Dr. Annalisa Jenkins’ caliber join the board of Skye,” said Punit Dhillon, CEO and Chair of Skye.
Retrieved on:
Monday, February 26, 2024
OTCQB,
SAN,
IOP,
Glaucoma,
OE,
Blood,
Obesity,
OHT,
Eye,
Database,
Safety,
Biomarker,
CB1,
Ocular hypertension,
Patient,
THC,
Hyperaemia,
Trial of the century,
Isle of Skye,
Pharmaceutical industry All treated patients completed the study, with no early discontinuations due to adverse events.
Key Points:
- All treated patients completed the study, with no early discontinuations due to adverse events.
- “Because this trial completed enrollment ahead of schedule, our initially intended interim data report based on partial enrollment is unnecessary.
- Skye is evaluating SBI-100 OE’s ability to lower IOP, safety and relevant biomarkers in patients with POAG or OHT.
- Low rate of hyperaemia (red eyes) of 8.4% compared to higher rates in other leading classes of glaucoma drugs.
Obesity,
OE,
Patient,
PIPE,
Richard Driehaus,
Leptin,
Fasting,
Visium Asset Management,
Sale,
Ocular hypertension,
OTCQB,
Exchange,
CB1,
Safety,
Triglyceride,
Netarsudil,
Glaucoma,
Waist,
Cholesterol,
Security (finance),
Body composition,
Oppenheimer Holdings,
Pharmaceutical industry Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist
Key Points:
- Gross proceeds from the PIPE are expected to be $50.25 million, before deducting any placement agent fees and offering-related expenses.
- The PIPE financing is expected to close on January 31, 2024, subject to the satisfaction of customary closing conditions.
- The PIPE financing was co-led by a life sciences-focused investor and 5AM Ventures, with participation from Ally Bridge Group, Sphera Healthcare, Altium Capital, Driehaus Capital Management and other institutional investors.
- Piper Sandler is acting as the lead placement agent and Oppenheimer & Co. is acting as a placement agent for the PIPE financing.
Retrieved on:
Monday, December 11, 2023
GIP,
NAFLD,
Traffic barrier,
Cholesterol,
Food,
Șaeș,
IND,
Non-alcoholic fatty liver disease,
Drug discovery,
FDA,
Kidney disease,
Weight loss,
Syringe,
Trial of the century,
Half-life,
Obesity,
Investigational New Drug,
Chronic kidney disease,
OTCQB,
CNS,
CB1,
Biomarker,
Prediabetes,
Central nervous system,
Patient,
Safety,
Albuminuria,
Pharmaceutical industry SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced today that it plans to develop nimacimab, the Company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity. The Company has filed an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for the initiation of a Phase 2 clinical study of nimacimab in patients with obesity and chronic kidney disease.
Key Points:
- Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 receptor ("CB1"), which has been implicated as an important target in multiple cardiometabolic diseases including obesity and renal complications.
- Obesity and kidney disease are highly correlated: 80% of patients who have kidney disease are also obese; 30% of obese patients have kidney disease.
- Nimacimab effectively inhibits CB1 signaling and, based on preclinical and early clinical studies, is devoid of the CNS liabilities typically seen by small molecule drugs that target the CB1 receptor because it does not cross the blood-brain barrier.
- Skye owns the worldwide rights to nimacimab, with patents issued in the U.S. and other territories including claims to cannabinoid 1 receptor antibodies with inverse agonist function.
Retrieved on:
Tuesday, November 28, 2023
IOP,
Patient,
Hyperaemia,
Risk,
Trial of the century,
Blood,
MD,
SAN,
THC,
Eye,
Isle of Skye,
Intraocular pressure,
OHT,
Ocular hypertension,
OTCQB,
CB1,
Biomarker,
OE,
Safety,
Non-Euclidean geometry,
Glaucoma,
Pharmaceutical industry SBI-100 OE is a synthetic prodrug of tetrahydrocannabinol (“THC”) that is able to bind and activate CB1 receptors in key ocular tissues.
Key Points:
- SBI-100 OE is a synthetic prodrug of tetrahydrocannabinol (“THC”) that is able to bind and activate CB1 receptors in key ocular tissues.
- We are advancing the next generation of investigational drugs targeting the endocannabinoid system’s CB1 receptor,” said Punit Dhillon, Skye’s CEO and Chairman.
- “This Phase 2 study provides an avenue to confirm IOP-lowering ability and advance the potential for SBI-100 OE in treating ophthalmic disorders.
- In preclinical studies involving three different species, SBI-100 OE lowered IOP to a level and duration that compared favorably to the standard of care for treating glaucoma.
Retrieved on:
Tuesday, January 24, 2023
Isle of Skye,
Safety,
Ocular hypertension,
Severe cognitive impairment,
CDMO,
Trial of the century,
Molecule,
Eye,
Pharmacokinetics,
Glaucoma,
Intraocular pressure,
IOP,
Drug development,
University,
OE,
Pressure,
Clinical data management,
Valley,
Pharmaceutical industry,
MD,
PII Increased intraocular pressure (IOP) is a key risk factor in the progression of glaucoma, an eye disease that leads to blindness.
Key Points:
- Increased intraocular pressure (IOP) is a key risk factor in the progression of glaucoma, an eye disease that leads to blindness.
- Independent studies have demonstrated that activating the cannabinoid receptor-type 1 (CB1R) in ocular tissue mediates IOP-lowering.
- Skye initiated its first-in-human Phase 1 clinical study of SBI-100 OE in Australia in November and dosed the first cohort of healthy participants in December.
- “We learned a lot from the expertise that Skye brought in to supplement the production and manufacturing team at Pii.
